BioN­Tech bets on dif­fi­cult STING field via small mol­e­cule pact with a Pol­ish biotech

BioN­Tech is beef­ing up its rel­a­tive­ly thin small mol­e­cule pipeline by adding weight to a clin­i­cal­ly dif­fi­cult cor­ner of on­col­o­gy R&D: STING ag­o­nists. To do so, BioN­Tech is team­ing up with a 15-year-old Pol­ish biotech and dol­ing out €40 mil­lion, about $41.5 mil­lion, to start.

The deal is bro­ken in­to two parts: First, BioN­Tech ob­tains an ex­clu­sive glob­al li­cense to de­vel­op and mar­ket Ryvu Ther­a­peu­tics’ STING ag­o­nist port­fo­lio as small mol­e­cules, whether alone or in com­bi­na­tion with oth­er agents.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER